背景:子宫内膜异位症是育龄妇女常见的妇科疾病。常用的治疗方法,如内分泌和外科治疗,显示治疗效果差,复发概率高。因此,子宫内膜异位症需要新的治疗方法.
方法:在我们的研究中,聚多巴胺(PDA),来曲唑(LTZ),与琼脂糖(AG)水凝胶结合,构建了一种近红外控制药物递送的可注射水凝胶,称为LTZ-PDA@AG水凝胶,用于子宫内膜异位症的治疗。来曲唑的释放可以通过近红外光强度精确控制,暴露持续时间,聚多巴胺浓度,和水凝胶组合物。同时,我们从子宫内膜异位症患者的子宫内膜中分离出子宫内膜基质细胞,并构建大鼠子宫内膜异位症模型,验证LTZ-PDA@AG水凝胶的生物学效应。
结果:由于近红外光足够深的穿透,LTZ-PDA@AG水凝胶显示出高效光热治疗的高温增加。此外,较高的局部温度可以进一步增强来曲唑的扩散和渗透,从而在体内获得优异的治疗效果。重要的是,体内和体外试验证明了纳米复合水凝胶的内分泌-光热协同治疗能力和生物相容性。
结论:我们的工作提出了一种通过光热增强内分泌疗法治疗子宫内膜异位症的精确子宫内膜异位症的新概念。这是首次提出用于子宫内膜异位症的治疗,并显示出进一步临床转化的巨大潜力。
背景:不适用。合成了LTZ-PDA@AG水凝胶,并显示出高温升高,可在NIR下进行有效的光热治疗。本研究显示了纳米复合水凝胶用于内分泌-光热协同治疗的能力和生物相容性。
BACKGROUND: Endometriosis is a common gynecological disease in women of childbearing age. Commonly used treatment methods, such as endocrine and surgical therapies, display poor therapeutic effects with a high relapse probability. Thus, novel treatments for endometriosis are required.
METHODS: In our study, polydopamine (PDA), letrozole (LTZ), and agarose (AG) hydrogels were combined to construct an injectable hydrogel with near-infrared controlled drug delivery named LTZ-PDA@AG hydrogel for endometriosis treatment. The release of letrozole can be accurately controlled by the near-infrared light intensity, exposure duration, polydopamine concentration, and hydrogel composition. Meanwhile, we isolated endometrial stromal cells from endometrium in patients with endometriosis, and constructed the rats\' model of endometriosis to verify the biological effects of LTZ-PDA@AG hydrogel.
RESULTS: Owing to the sufficiently deep penetration of near-infrared light, the LTZ-PDA@AG hydrogel displayed a high temperature increase for efficient photothermal therapy. In addition, high local temperatures can further enhance the diffusion and penetration of letrozole, thereby achieving excellent therapeutic effect in vivo. Importantly, the in vivo and vitro test demonstrated the capacity of the nanocomposite hydrogel for endocrine-photothermal synergistic therapy and the biocompatibility.
CONCLUSIONS: Our work proposes a novel concept for precision endometriosis therapy by photothermal-enhanced endocrine therapy for endometriosis, which is proposed for the first time for the treatment of endometriosis and demonstrates excellent potential for further clinical translation.
BACKGROUND: Not applicable. LTZ-PDA@AG hydrogels were synthesized and displayed a high temperature increase for efficient photothermal therapy under NIR. The present study shows the capacity of the nanocomposite hydrogel for endocrine-photothermal synergistic therapy and the biocompatibility.